WiCON | Pharma China (Web Edition)

ONLINE ENQUIRY

WiCON International Group
21 Bridge Street
Metuchen, NJ 08840, USA
Tel/Fax: +1 801-751-5728
info@pharmachinaonline.com

Affiliated Companies
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com

BJ Jicai PharmTech
Oriental Kenzo Plaza
Beijing, China
Tel: +86 10 84476010
info@pharmachinaonline.com

Lesson from China's National Negotiation of Drug Prices in 2020 In December 2020, Chinas National Healthcare Security Administration (NHSA) published the 2020 National Reimbursement Drug List (2020 NRDL), continuing the trend toward s...
(1/21/2021)

Lesson from China's National Negotiation of Dr... (1/21/2021)

Chinese Civil Code Introduces Punitive Damages... (1/21/2021)

New Judicial Interpretation in China Strengthe... (1/21/2021)

Coronavirus in China: 2021 Outlook Brightens f... (1/21/2021)

Reform Has Unleashed Chinese Drugs Innovation ... (1/21/2021)

BioWorld: Luye's Schizophrenia Drug Approval i... (1/19/2021)

PL: Facing Aggressive Price Cuts at Home, Chin... (1/19/2021)

Top JPMorgan Banker Sees Steady Supply of Chin... (1/18/2021)

Novartis, Once Wary of Chinese M&A, Dives into... (1/14/2021)

Pharma Companies to Cut Prices of News Drugs b... (1/14/2021)

What Do Novartis Deal, PD-1 Competition In Chi... (1/14/2021)

Reform Has Unleashed Chinese Drugs Innovation ... (1/14/2021)

CDE Solicits Comments on Two Technical D... (1/27/2021) Biogen Employee Traveling to China with ... (1/27/2021) Novartis Aims to Double China Business b... (1/27/2021) NH Reports on Chinese OTC Sleep Aids Mar... (1/27/2021) NH Reports Latest Data on Chinese Smokin... (1/27/2021) NH Reports on Chinese OTC Eye Care Marke... (1/27/2021) CDE Issues the Technical Guidelines for ... (1/26/2021) CDE Issues the Technical Guidelines for ... (1/26/2021) Photocure Partners with Asieris MediTech... (1/26/2021) AstraZeneca Granted Additional Indiciati... (1/26/2021) Antengene Granted Chinese IND Approval... (1/26/2021) EUSA and BeiGene Announce Acceptance of... (1/26/2021) China's Meituan to Shut Down Healthcare ... (1/25/2021) NMPA Publicizes the List of Reference Fo... (1/25/2021) NMPA Revises Packages Inserts of Gefitin... (1/25/2021) CDE Issues the ICH Guidelines E9(R1), S5... (1/25/2021) NMPA Issues the List of Reference Formul... (1/25/2021) Recent Executive Moves (1/22/2021)

NH Reports on Chinese OTC Eye Care Market in MAT 09/202... NH Reports Latest Data on Chinese Smoking Control Marke... NH Reports on Chinese OTC Sleep Aids Market in MAT 09/2... Domestic PD-1s in the 2020 NRDL Negotiated Entry: Winne... China to Lower Import Tariffs on 883 Products with Zero...

Novartis Aims to Double China Business by 2024 AstraZeneca Granted Additional Indiciation for Asthma D... Photocure Partners with Asieris MediTech to Commerciali... CDE Issues the Technical Guidelines for Drug Interactio... NMPA Issues the List of Reference Formulations for GQCE...

CDE Solicits Comments on Two Technical Documents for Ph... CDE Issues the Technical Guidelines for Bioequivalence ... NMPA Publicizes the List of Reference Formulations for ... NMPA Announces OTC Switch of Budesonide Nasal Spray NMPA Revises Packages Inserts of Pamidronate Disodium I...

China's Meituan to Shut Down Healthcare Mutual Aid Prog... JPO Issues Bidding Documents for the Fourth Batch of VB... NHSA Highlights Ten Major Tasks in 2021 Swiss Re Sees Short-term Health insurance as Growth Dri... NHSA Issues Two Interim Rules for Management of BMI Des...

USTR Unleashes 2020 Report for China's WTO Compliance H... China Ups Drug Regulation, Biosecurity and IPR Protecti... China's New Export Control Law Triggers More Trade and ... Genscript Chairman Arrested on Suspected Smuggling Offe... Wanbangde Pharma Fined CNY 2.5M for Abuse of Market Mon...

India Probes Alleged API Dumping by Chinese Companies China Increases Prices of Key Drug Ingredients by Up To... U.S. Introduces A 'Buy American First' Pharma Executive... Fitch: No Near-Term Impact on Chinese API Makers as Pha... Indian Firms Challenged by API Price Hikes by Chinese S...

EUSA and BeiGene Announce Acceptance of a Biologics Li... Antengene Granted Chinese IND Approval for ATG-010 (S... Everest Medicines Granted Clinical Trial Approval of S... AZ and MSD's Granted Priority Review for New Indication... GSK Granted Priority Review for NDA of Two-in-One HIV D...

BioAtla and BeiGene Revise Global Deal for Novel Condit... Pfizer to Absorb Mylan, Creating Global Generic Powerho... PhRMA Calls for Trade Deals That Force Countries to Pay... IQVIA: Global Pharma to Grow Slower in the Next Five Ye... Pfizer and GSK Announce JV to Create a Global Consumer ...

Biogen Employee Traveling to China with COVID-19 Last M... Recent Executive Moves Chinese Couple Plead Guilty To Stealing Trade Secrets ... Yidu CEO: A New Chinese Healthcare Billionaires Is Bor... Recent Executive Moves

Upcoming Event: Plenareno Pharma Middle East Virtual Co... Live Podcast - VC & Impact Investing in China: Investin... 2020 Fall/Winter Promotion - Pharma China publications USTR Satisfied with China's Implementatin of Phase 1 US... U.S.-China ESRC Hearing: China's Evolving Healthcare Sy...

Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...

WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...

Pharma China on Twitter and Faceboo... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu... WiCON to Hold Pharma China Annual F... WiCON Publishes the China Pharmaceu...